Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
13.22
-0.18 (-1.34%)
At close: Oct 26, 2026, 4:00 PM EDT
13.28
+0.06 (0.45%)
After-hours: Oct 26, 2026, 7:30 PM EDT
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 298 employees as of December 31, 2025. The number of employees increased by 28 or 10.37% compared to the previous year. That makes Syndax Pharmaceuticals the 23,895th largest employer in the world and 3,073rd in the United States.
Employees
298
Change (1Y)
28
Growth (1Y)
10.37%
Revenue / Employee
$846,480
Profits / Employee
-$740,822
Market Cap
1.18B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 298 | 28 | 10.37% | 298 | 0 |
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kardigan | 241 |
| Omeros | 175 |
| Alpha Tau Medical | 121 |
| Bicara Therapeutics | 103 |
| Verastem | 102 |
| Silence Therapeutics | 88 |
| Rapport Therapeutics | 84 |
| GH Research | 73 |
SNDX News
- 17 hours ago - Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 - GlobeNewsWire
- 9 days ago - SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
- 11 days ago - Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List - GlobeNewsWire
- 13 days ago - Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PRNewsWire
- 13 days ago - Syndax valuation unchanged after trial miss, says H.C. Wainwright - TheFly
- 13 days ago - Syndax selloff brings attractive entry point, says Citi - TheFly
- 13 days ago - Syndax price target lowered to $23 from $26 at BofA - TheFly
- 14 days ago - Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint - TheFly